Bifidobacteria have been investigated for their potential role in managing Fatty Liver Disease, particularly non-alcoholic fatty liver disease (NAFLD). Several preclinical studies and small clinical trials suggest that supplementation with Bifidobacteria-containing probiotics may help improve liver-related parameters. The proposed mechanisms include modulation of the gut microbiota, reduction of intestinal permeability ("leaky gut"), suppression of liver inflammation, and improved lipid metabolism. Dysbiosis—an imbalance in gut bacteria—has been associated with NAFLD, and restoring a healthy microbiome is thought to mitigate disease progression.

Small randomized controlled trials and meta-analyses (e.g., Ma YY et al., 2013, PLoS One; Loman BR et al., 2018, World J Gastroenterol) have reported that multi-strain probiotics containing Bifidobacteria can reduce liver enzyme levels (ALT, AST), decrease hepatic fat content, and improve markers of inflammation and insulin resistance in NAFLD patients. However, these studies often use combinations of probiotics, making it difficult to isolate the specific effects of Bifidobacteria. There is currently insufficient large-scale, high-quality evidence to recommend Bifidobacteria alone as a standard therapy, but the existing data are promising enough to justify ongoing research and cautious clinical interest.

In summary, the use of Bifidobacteria for fatty liver disease is supported by preliminary scientific evidence, but more robust clinical trials are needed to confirm efficacy and establish optimal strains, dosages, and treatment durations.